Meeting
2019 Genitourinary Cancers Symposium
The impact of histologic variants of urothelial carcinoma on clinical outcomes following trimodal bladder-preserving therapy.
Authors
Yoshiyuki Nagumo
University of Tsukuba, Tsukuba, Japan
Yoshiyuki Nagumo , Shuya Kandori , Tomokazu Kimura , Takashi Kawahara , Takahiro Kojima , Koji Kawai , Hitoshi Ishikawa , Hiroyuki Nishiyama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 421)
DOI
10.1200/JCO.2019.37.7_suppl.421
Abstract #
421
Poster Bd #
H12
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Clinical outcomes of patients with histologic variants of urothelial carcinoma treated with tetra-modality bladder-sparing protocol incorporating consolidative partial cystectomy.
First Author: Toshiki Kijima
Poster
2020 Genitourinary Cancers Symposium
The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle invasive bladder cancer: A single-arm prospective study.
First Author: Hiroaki Matsumoto
Poster
2019 Genitourinary Cancers Symposium
Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose-dense MVAC.
First Author: Yongjune Lee
Poster
2017 Gastrointestinal Cancers Symposium
Comparison between local and extended field radiotherapy, including regional nodes radiotherapy, in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer.
First Author: Yukihiro Nakatani